HOME >> MEDICINE >> NEWS
NIAID launches program to improve medical tools against emerging infectious diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded 14 contracts totaling more than $73 million to fund the Large-Scale Antibody and T Cell Epitope Discovery Program, an initiative aimed at quickly identifying the regions of selected infectious agents that elicit immune reactions. The study of these regions, known as epitopes, promises to uncover targets for new and improved vaccines, therapies and diagnostic tools against potential bioterror agents as well as emerging/re-emerging infectious diseases such as West Nile virus and influenza. NIAID will make information on each newly identified epitope freely available to scientists through a searchable online database currently under development.

"Elucidating the basic mechanisms of immune function is a major focus of our biodefense research agenda," says Anthony S. Fauci, M.D., director of NIAID. "The information generated by this program will deepen our understanding of how components of the immune system defend against certain infectious agents, enabling researchers to design new and improved medical countermeasures."

"Researchers have been conducting epitope discovery for many years, but generally on a small scale," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation. "This initiative, however, will yield new knowledge about antigenic epitopes from a wide variety of microbes, including agents that might be used in a bioterrorist attack."

Epitopes are recognized by the body's B and T cells, white blood cells that detect an invading pathogen. Each B and T cell is specific for a particular antigen, meaning that each can only bind to a certain foreign molecular structure. This "specificity" is determined by the receptors on the surface of each cell.

Both B- and T-cell specificity as well as the diverse functions of these cells determine the effectiveness of an immu
'"/>

Contact: Paul Williams
pw81y@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
1-Nov-2004


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
8. NIAID rotavirus vaccine licensed for commercialization
9. Second NIAID SARS vaccine candidate helps mice fend off SARS
10. NIAID vaccine protects against SARS virus infection in mice
11. NIAID Ebola vaccine enters human trial

Post Your Comments:
(Date:4/21/2015)... 2015 Carinsurancesavings.biz has released a new blog ... surveillance and explaining the impact on a uto insurance ... and supervised may be eligible for advantageous auto insurance discounts. ... simple and efficient way. This will also help them get ... simple way. , Finding low cost coverage is no longer ...
(Date:4/21/2015)... 2015 Optimity Advisors ( Optimity), ... firm that helps clients in complex industries navigate ... the Association of Community Affiliated Plans ... represents 58 local, not-for-profit, community-affiliated Safety Net Health ... people primarily enrolled in public or state-sponsored coverage ...
(Date:4/21/2015)... CO (PRWEB) April 21, 2015 ... Management , a new knowledge management solution that ... and publishing of policies and procedures. With Quark ... create reusable content that is easy to save, ... is susceptible to risk and compliance issues. Examples ...
(Date:4/21/2015)... When a bandage sticks to an injury ... to solve this problem two inventors from Festus, Mo., ... bandage helps a cut, burn, abrasion or wound heal ... exposure. The bandage is easy to use, versatile and ... submitted to the St. Louis office of InventHelp. It ...
(Date:4/21/2015)... Ill. (PRWEB) April 21, 2015 The ... the late cosmetic dermatologist Fredric S. Brandt, M.D., by ... Dr. Brandt, an ASDS member since 1982, died earlier ... The funds are designed to provide opportunities for ASDS ... field of cosmetic dermatology that Dr. Brandt held so ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes Offer Excellent Security for A Car 2Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 2Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 3Health News:ASDS honors the legacy of Dr. Fredric Brandt 2Health News:ASDS honors the legacy of Dr. Fredric Brandt 3Health News:ASDS honors the legacy of Dr. Fredric Brandt 4
(Date:4/21/2015)... 21, 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that the abstract describing ... from the Phase 2 clinical trial of the Company,s ... selected for an oral presentation at the 2015 American ... held in Chicago, Illinois May ...
(Date:4/20/2015)... 2015  Following is the daily "Profile America" feature ... MEDICINE Profile America — ... insulin —became available for general use this month in ... from diabetes. Insulin is a hormone produced by the ... in the human body. It was first isolated the ...
(Date:4/20/2015)... Ireland , April 20, 2015 ... that Charles M. Mayr , Chief Communications ... due to health reasons.  In conjunction with Mayr,s ... will assume the role of Chief Communications Officer, ... Kelly served as Senior Vice President, Chief Communications ...
Breaking Medicine Technology:Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 2Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 3U.S. Census Bureau Daily Feature for April 21 2Actavis Announces Retirement of Charles M. Mayr 2Actavis Announces Retirement of Charles M. Mayr 3
Cached News: